Erenumab for episodic migraine

被引：5

作者：

Datta, Abhigyan ^{[1
]}

Gupta, Sahil ^{[2
]}

Maryala, Shashi ^{[3
]}

Aggarwal, Vikram ^{[4
]}

Chopra, Pooja ^{[5
]}

Jain, Sameer ^{[6
]}

机构：

[1] Maulana Azad Med Coll, New Delhi 110002, India

[2] Southern Illinois Healthcare, Carbondale, IL 62901 USA

[3] Gandhi Med Coll, Secunderabad 500003, Telangana, India

[4] UT Southwestern Med Ctr, Dallas, TX 75390 USA

[5] Bux Pain Management, 217 3rd St, Danville, KY 40422 USA

[6] Pain Treatment Ctr Amer, Little Rock, AR 72205 USA

来源：

PAIN MANAGEMENT | 2022年 / 12卷 / 05期

关键词：

Aimovig; CGRP antagonists; episodic migraine; erenumab; headache; migraine; GENE-RELATED PEPTIDE; DOUBLE-BLIND; AMG; 334; PATHOPHYSIOLOGY; EFFICACY; HEALTHY; SAFETY; TRIAL;

D O I：

10.2217/pmt-2021-0077

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly doses of 70 or 140 mg when given for a period of 9-12 weeks. Post hoc analyses have also shown long-term maintenance of efficacy. Clinical trials have found erenumab at doses of both 70 and 140 mg to have a favorable safety profile. Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.

引用

页码：587 / 594

页数：8

共 52 条

[1] Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David W.
Xue, Fei
Zhang, Feng
Paiva da Silva Lima, Gabriel
Cheng, Sunfa
Mikol, Daniel D.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (05) : 1716 - 1725
[2] Migraine and the trigeminovascular system-40 years and counting
Ashina, Messoud
Hansen, Jakob Moller
Thien Phu Do
Melo-Carrillo, Agustin
Burstein, Rami
Moskowitz, Michael A.
[J]. LANCET NEUROLOGY, 2019, 18 (08) : 795 - 804
[3] Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David
Rippon, Gregory A.
Klatt, Jan
Xue, Fei
Chia, Victoria
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
[J]. CEPHALALGIA, 2019, 39 (11) : 1455 - 1464
[4] Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Barbanti, Piero
Aurilia, Cinzia
Egeo, Gabriella
Fofi, Luisa
Cevoli, Sabina
Colombo, Bruno
Filippi, Massimo
Frediani, Fabio
Bono, Francesco
Grazzi, Licia
Salerno, Antonio
Mercuri, Bruno
Carnevale, Antonio
Altamura, Claudia
Vernieri, Fabrizio
[J]. HEADACHE, 2021, 61 (02): : 363 - 372
[5] The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Broessner, Gregor
Reuter, Uwe
Bonner, Jo H.
Dodick, David W.
Hallstrom, Yngve
Picard, Hernan
Zhang, Feng
Lenz, Robert A.
Klatt, Jan
Mikol, Daniel D.
[J]. HEADACHE, 2020, 60 (09): : 2026 - 2040
[6] Migraine: Multiple Processes, Complex Pathophysiology
Burstein, Rami
Noseda, Rodrigo
Borsook, David
[J]. JOURNAL OF NEUROSCIENCE, 2015, 35 (17) : 6619 - 6629
[7] Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
Buse, Dawn C.
Lipton, Richard B.
Hallstrom, Yngve
Reuter, Uwe
Tepper, Stewart J.
Zhang, Feng
Sapra, Sandhya
Picard, Hernan
Mikol, Daniel D.
Lenz, Robert A.
[J]. CEPHALALGIA, 2018, 38 (10) : 1622 - 1631
[8] Chou DE., 2019, NEUROLOGY, V92
[9] Ubrogepant for the treatment of migraine
Curto, Martina
Capi, Matilde
Cipolla, Fabiola
Cisale, Giusy Ylenia
Martelletti, Paolo
Lionetto, Luana
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (07) : 755 - 759
[10] Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
de Hoon, Jan
van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
[J]. CEPHALALGIA, 2019, 39 (01) : 100 - 110

← 1 2 3 4 5 6 →